Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2020 on request of the sponsor.
On 6 February 2009, orphan designation (EU/3/08/608) was granted by the European Commission to Immunomedics GmbH, Germany, for Yttrium (90Y)-DOTA-radiolabelled humanized monoclonal antibody against mucin 1 for the treatment of pancreatic cancer.
EU/3/08/608: Public summary of positive opinion for orphan designation of yttrium (90Y)-DOTA-radiolabelled humanized monoclonal antibody against mucin 1 for the treatment of pancreatic cancer (PDF/335.31 KB)
First published: 26/06/2009
Last updated: 06/03/2020
Yttrium (90Y)-DOTA-radiolabelled humanized monoclonal antibody against mucin 1
|Disease / condition||
Treatment of pancreatic cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.